Molecular Diagnostics and NAT Market

Molecular diagnostics is the application of medical and microbiological technologies to the medical imaging science, in order to analyze biological markers present in the proteome and genome, which also includes the study of how an individual express his/her genes as proteins. The is an important diagnostic and patient monitoring technique, which not only diagnose the disease but also access the risks involved in treatment and suggest suitable therapies for the patients. Nucleic acid test, or nucleic acid amplification test (NAT/NAAT) is another molecular technology used in identification of a bacterium or virus. NAT comprises of all the tests and technologies used to identify genetic material of infecting virus or organism.

Molecular Diagnostics and NAT Market contains market size and forecasts of Molecular Diagnostics and NAT in Global, including the following market information:

• Global Molecular Diagnostics and NAT Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

The global Molecular Diagnostics and NAT market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Amplification Technologies Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Molecular Diagnostics and NAT include Roche, Abbott, BD, Biomerieux, Qiagen, Thermo Fisher Scientific, Agilent, GenMark and Siemens Healthcare and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Molecular Diagnostics and NAT companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Molecular Diagnostics and NAT Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Molecular Diagnostics and NAT Market Segment Percentages, by Type, 2021 (%)

• Amplification Technologies
• Amplified Gene Detection Technologies
• DNA And Oligonucleotide Microarrays
• Gene Sequencing

Global Molecular Diagnostics and NAT Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Molecular Diagnostics and NAT Market Segment Percentages, by Application, 2021 (%)

• Hospitals and Clinics
• Research Institutes
• Diagnostic Centers

Global Molecular Diagnostics and NAT Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Molecular Diagnostics and NAT Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Molecular Diagnostics and NAT revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Molecular Diagnostics and NAT revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Roche
• Abbott
• BD
• Biomerieux
• Qiagen
• Thermo Fisher Scientific
• Agilent
• GenMark
• Siemens Healthcare
• AutoGenomics